| Tier 1 Price Range | $200-280/kg (EP + CEP) |
|---|---|
| Tier 2 Price Range | $140-220/kg (EP/USP, no CEP) |
| Tier 3 Price Range | $100-150/kg (non-pharmacopoeia) |
| Tier 1 Key Feature | Active DMF and/or CEP; regular regulatory inspections |
| Tier 2 Key Feature | GMP operations; may hold filings or be in process |
| Tier 3 Key Feature | Competitive pricing; limited regulatory filings |
| Tier 1 Global Share | ~81% (top 5 manufacturers) |
| China Active Producers | ~6-8 (across all tiers) |
| Evaluation Criteria | 10-point framework |
Not all UDCA API manufacturers are the same. A supplier that works for a generic formulation in an emerging market may be inadequate for a branded drug filing in Europe, and a supplier that meets FDA requirements may be too expensive for a research-grade application. This guide classifies UDCA API manufacturers into three tiers based on regulatory filings, GMP compliance, quality infrastructure, and market positioning. It provides a 10-criteria comparison framework that pharmaceutical buyers can use to evaluate suppliers and match them to their specific market requirements.
Tier 1 UDCA manufacturers hold active, internationally recognized regulatory filings and supply API directly to multinational pharmaceutical companies. They are the reference standard for UDCA quality.
ICE Pharma (Italy/India), PharmaZell GmbH (Germany), Dipharma Francis (Italy), Daewoong Chemical (South Korea), and select Chinese manufacturers such as Zhongshan Bailing Pharmaceutical and Sichuan Xieli Pharmaceutical (which holds cGMP, EU GMP, Japan GMP, and COFEPRIS certifications with both DMF and CEP available for UDCA).
Tier 1 UDCA commands $200-280/kg. The price premium reflects regulatory costs (CEP fees, inspection hosting, stability programs), quality infrastructure investment, and the value of reduced regulatory burden for the buyer. For an EU marketing authorization, a CEP from a Tier 1 supplier eliminates the need to submit detailed API data in the dossier -- a time and cost saving that justifies the higher API price for many buyers.
Tier 2 manufacturers operate under GMP conditions and produce pharmacopoeia-grade UDCA, but their international regulatory filings are limited, in process, or held through trading partners rather than directly.
Hunan Erkang Pharmaceutical, Hangzhou Pingchuang Pharmaceutical, Hebei Huarui Pharmaceutical, Zhejiang Hisun Pharmaceutical, Zhejiang Garden Biotech, and Shaanxi Huike Biological Technology (all China). Lacerta Group and Biochem Pharmaceutical Industries (India) are also Tier 2, with some holding FDA/EMA-compliant GMP certifications.
Tier 2 UDCA prices at $140-220/kg. The 25-40% discount versus Tier 1 reflects lower regulatory overhead and the fact that the buyer must take on more of the regulatory burden. For emerging-market pharmaceutical manufacturers, Tier 2 UDCA offers pharmacopoeia quality at a cost that enables competitive finished-product pricing. The trade-off is that the buyer must conduct more thorough due diligence: verifying GMP compliance, auditing the facility, and confirming that the documentation package will support their regulatory filing.
Tier 3 manufacturers produce UDCA at competitive prices for non-regulated applications. They operate at smaller scale, with limited regulatory filings, and serve markets where pharmacopoeia-grade certification is not required.
Smaller Chinese manufacturers including Keaixin Bio-Chemical, Liaoning Wangyuan Pharmaceutical, and Suzhou Tianlu. Regional Indian producers such as Biotavia Labs and Arcelor Chemicals also operate in this tier.
Tier 3 UDCA at $100-150/kg can be 50% or more below Tier 1 pricing. For applications where the regulatory pathway does not require pharmacopoeia-grade certification, Tier 3 offers a cost-effective option. Buyers should verify purity independently (CoA from an accredited third-party laboratory), confirm that the material is suitable for their specific application, and ensure that their downstream customers and regulators accept non-pharmacopoeia starting material.
The table below compares UDCA API manufacturers across the 10 criteria that matter most for pharmaceutical procurement. Use this as a reference when evaluating suppliers.
| Criteria | Tier 1 | Tier 2 | Tier 3 |
|---|---|---|---|
| 1. DMF Status | Active Type II DMF, reviewed by FDA | DMF submitted or in preparation; may be held by trading partner | No DMF or lapsed DMF |
| 2. CEP Status | Active CEP granted by EDQM | CEP application in progress or not initiated | No CEP |
| 3. GMP Inspection History | Regular FDA/EDQM inspections; clean record or minor observations | National GMP certification; limited international inspection history | ISO 9001 or basic manufacturing permit; infrequent inspections |
| 4. Impurity Control | Full impurity profile characterized; CDCA < 0.5%, lithocholic acid < 0.1% | Meets monograph limits; impurity profile may not be fully characterized | Basic purity testing; monograph limits not guaranteed |
| 5. Batch Consistency | High; validated processes with statistical process control | Moderate; process validation may be limited or in progress | Variable; batch-to-batch consistency not guaranteed |
| 6. Documentation Package | Complete: CEP/DMF, full CoA, stability data, TSE/BSE, residual solvents, elemental impurities | Partial: CoA, GMP certificate, MSDS; stability data and regulatory filings may be incomplete | Basic: CoA (abbreviated), MSDS |
| 7. Lead Time | 8-12 weeks (documentation and regulatory review add time) | 4-10 weeks | 2-6 weeks |
| 8. MOQ Flexibility | Typically 25-50 kg minimum; less flexible on small orders | 10-25 kg; more flexible for established relationships | 5-10 kg; flexible on small orders |
| 9. Audit Readiness | Prepared for unannounced regulatory audits; dedicated quality systems staff | Can accommodate scheduled customer audits; may require notice | Limited audit infrastructure; remote or paper-based review more common |
| 10. Pricing (per kg) | $200-280 | $140-220 | $100-150 |
The 10-criteria framework above should be used as a starting point, not a final evaluation. Each buyer's weighting of these criteria will differ based on their market, regulatory pathway, and risk tolerance. A buyer filing an ANDA in the US cannot compromise on criteria 1 (DMF status) and 3 (GMP inspection history), while a buyer serving an emerging market without stringent regulatory requirements may prioritize criteria 8 (MOQ flexibility) and 10 (pricing) over regulatory filings.
If you are filing an ANDA in the US, a marketing authorization application in the EU, or a new drug application in Japan, Tier 1 is your only option. The active Type II DMF (US) or CEP (EU) is a regulatory prerequisite, and the documentation package that Tier 1 suppliers provide -- full stability data, validated analytical methods, and regulatory affairs support -- will save months of dossier preparation time. The price premium of Tier 1 UDCA should be evaluated against the total cost of regulatory filing, including the internal regulatory affairs resources required to compile a full API section from a Tier 2 supplier without a CEP. In many cases, the higher API cost is offset by reduced regulatory burden.
For pharmaceutical manufacturers in Latin America, Southeast Asia, the Middle East, and Africa, Tier 2 UDCA offers pharmacopoeia-quality API at a cost that supports competitive finished-product pricing. Many emerging-market regulatory authorities accept a GMP certificate from a recognized authority plus the manufacturer's CoA without requiring a CEP or FDA-reviewed DMF. Tier 2 suppliers can typically provide this documentation package. The buyer's responsibility is to verify that the specific Tier 2 supplier meets their local regulatory requirements and to conduct sufficient due diligence (GMP audit, retain sample testing, stability evaluation) to confirm that the quality is consistent.
Tier 3 UDCA is appropriate for applications where pharmacopoeia certification is not required: veterinary products not intended for food-producing animals, cosmetic ingredients, research and development, process development, and certain food supplement markets. The cost advantage of Tier 3 can be 50% or more versus Tier 1. Buyers should verify the purity independently, confirm that the material is fit for the intended use, and ensure that downstream customers are aware of and accept the grade of UDCA being used. Using Tier 3 UDCA in a regulated human pharmaceutical product is not permitted and carries regulatory risk including potential product recall.
Some pharmaceutical companies adopt a mixed-tier sourcing strategy: Tier 1 UDCA for their regulated-market products and Tier 2 UDCA for their emerging-market products, with the same supplier relationship spanning both tiers. This approach maximizes quality where required and cost where permissible, while consolidating supplier relationships. The key is to maintain clear segregation between the two material streams in receiving, storage, and manufacturing, with documented traceability from receipt to finished product.